The first platform trial for amyotrophic lateral sclerosis (ALS), which individually evaluated four experimental drugs, failed to meet key primary endpoints. Still, investigators view the trial as ...
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate potential treatments for amyotrophic lateral sclerosis (ALS), with results ...
Hosted on MSN
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard treatment for amyotrophic lateral sclerosis slowed functional decline and ...
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...
When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...
The phase III trial of reldesemtiv did not meet its primary endpoint in amyotrophic lateral sclerosis (ALS). Reldesemtiv also demonstrated no effect on key secondary endpoints. The trial was stopped ...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few treatment options. Since 2018, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), a ...
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients LA JOLLA, Calif., July 24, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results